BiotechTube

JR-141 + Idursulfase + JR-141 or Idursulfase

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis II

Conditions

Mucopolysaccharidosis II

Trial Timeline

Feb 14, 2022 → Oct 31, 2027

NCT ID
NCT04573023

About JR-141 + Idursulfase + JR-141 or Idursulfase

JR-141 + Idursulfase + JR-141 or Idursulfase is a phase 3 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is active. This product is registered under clinical trial identifier NCT04573023. Target conditions include Mucopolysaccharidosis II.

What happened to similar drugs?

5 of 14 similar drugs in Mucopolysaccharidosis II were approved

Approved (5) Terminated (1) Active (9)
✅laronidaseSanofiApproved
✅LaronidaseSanofiApproved
✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
✅LaronidaseSanofiApproved
✅NaglazymeBioMarin PharmaceuticalApproved
🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04573023Phase 3Active

Competing Products

20 competing products in Mucopolysaccharidosis II

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
29
anakinraSwedish Orphan BiovitrumPhase 1/2
32
laronidaseSanofiApproved
43
LaronidaseSanofiApproved
43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
40
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
40
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
40
LaronidaseSanofiApproved
35
JR-141JCR PharmaceuticalsPhase 2/3
38
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
36
JR-446JCR PharmaceuticalsPhase 1/2
39
JR-171JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2
39
JR-141JCR PharmaceuticalsPhase 3
47
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2/3
42